Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lester Reich

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Drug Safety|March 10, 2006
Extension of points on clarifying terminology in drug safetyManfred Hauben, Lester Reich, Flic Gabbay
Drug Safety|January 27, 2007
Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactionsManfred Hauben, Sebastian Horn, Lester Reich
European Journal of Clinical Pharmacology|December 25, 2004
Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithmsManfred Hauben, Lester Reich, Stephanie Chung
Pharmacoepidemiology and Drug Safety|June 29, 2006
Reports of hyperkalemia after publication of RALES--a pharmacovigilance studyManfred Hauben, Lester Reich, Charles M Gerrits
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2007
Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance toolsManfred Hauben, Sebastian Horn, Lester Reich, et al.
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Cutaneous and Ocular Toxicology|March 12, 2008
Drug-induced psoriasis: results from pharmacovigilance tools under investigationManfred Hauben, Lester Reich, Suzanne Magliano, et al.
European Journal of Gastroenterology & Hepatology|December 1, 2007
Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysisManfred Hauben, Ferdinando Vegni, Lester Reich, et al.
Drug Safety|November 15, 2011
Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literatureMuhammad Younus, Michelle Kissner, Lester Reich, et al.
Drug Safety|November 27, 2007
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES)Manfred Hauben, Lester Reich, Charles M Gerrits, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Drug Safety|March 10, 2006
Extension of points on clarifying terminology in drug safetyManfred Hauben, Lester Reich, Flic Gabbay
Drug Safety|January 27, 2007
Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactionsManfred Hauben, Sebastian Horn, Lester Reich
European Journal of Clinical Pharmacology|December 25, 2004
Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithmsManfred Hauben, Lester Reich, Stephanie Chung
Pharmacoepidemiology and Drug Safety|June 29, 2006
Reports of hyperkalemia after publication of RALES--a pharmacovigilance studyManfred Hauben, Lester Reich, Charles M Gerrits
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2007
Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance toolsManfred Hauben, Sebastian Horn, Lester Reich, et al.
Drug Safety|June 1, 2007
'Extreme duplication' in the US FDA Adverse Events Reporting System databaseManfred Hauben, Lester Reich, James DeMicco, et al.
Cutaneous and Ocular Toxicology|March 12, 2008
Drug-induced psoriasis: results from pharmacovigilance tools under investigationManfred Hauben, Lester Reich, Suzanne Magliano, et al.
European Journal of Gastroenterology & Hepatology|December 1, 2007
Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysisManfred Hauben, Ferdinando Vegni, Lester Reich, et al.
Drug Safety|November 15, 2011
Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literatureMuhammad Younus, Michelle Kissner, Lester Reich, et al.
Drug Safety|November 27, 2007
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES)Manfred Hauben, Lester Reich, Charles M Gerrits, et al.
Pageof 3